WARNING: FETAL TOXICITY When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus [see Warnings and Precautions (5.1)]. WARNING: FETAL TOXICITY See full prescribing information for complete boxed warning. When pregnancy is detected, discontinue COZAAR as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus. (5.1)
Use: Labeled indications
- Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old.
- Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy.
- Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
Full indications and usage US FDA label
1 INDICATIONS AND USAGE COZAAR is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
(1.1) Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. (1.2) Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
(1.3) 1.1 Hypertension COZAAR ® is indicated for the treatment of hypertension in adults and pediatric patients 6 years of age and older, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and nonfatal cardiovascular (CV) events, primarily strokes and myocardial infarction. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including losartan.
Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than 1 drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program's Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC).
Numerous antihypertensive drugs, from a variety of pharmacologic classes and with different mechanisms of action, have been shown in randomized controlled trials to reduce cardiovascular morbidity and mortality, and it can be concluded that it is blood pressure reduction, and not some other pharmacologic property of the drugs, that is largely responsible for those benefits. The largest and most consistent cardiovascular outcome benefit has been a reduction in the risk of stroke, but reductions in myocardial infarction and cardiovascular mortality also have been seen regularly.
Elevated systolic or diastolic pressure causes increased cardiovascular risk, and the absolute risk increase per mmHg is greater at higher blood pressures, so that even modest reductions of severe hypertension can provide substantial benefit. Relative risk reduction from blood pressure reduction is similar across populations with varying absolute risk, so the absolute benefit is greater in patients who are at higher risk independent of their hypertension (for example, patients with diabetes or hyperlipidemia), and such patients would be expected to benefit from more aggressive treatment to a lower blood pressure goal.
Some antihypertensive drugs have smaller blood pressure effects (as monotherapy) in Black patients, and many antihypertensive drugs have additional approved indications and effects (e.g., on angina, heart failure, or diabetic kidney disease). These considerations may guide selection of therapy. COZAAR may be administered with other antihypertensive agents. 1.2 Hypertensive Patients with Left Ventricular Hypertrophy COZAAR is indicated to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy, but there is evidence that this benefit does not apply to Black patients [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)]. 1.3 Nephropathy in Type 2 Diabetic Patients COZAAR is indicated for the treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria (urinary albumin to creatinine ratio ≥300 mg/g) in patients with type 2 diabetes and a history of hypertension.
In this population, COZAAR reduces the rate of progression of nephropathy as measured by the occurrence of doubling of serum creatinine or end stage renal disease (need for dialysis or renal transplantation) [see Clinical Studies (14.3)].
Contraindications
- Hypersensitivity to any component
- Coadministration with aliskiren in patients with diabetes
Contraindications (US label) US FDA label
4 CONTRAINDICATIONS COZAAR is contraindicated: In patients who are hypersensitive to any component of this product. For coadministration with aliskiren in patients with diabetes. Hypersensitivity to any component. (4) Coadministration with aliskiren in patients with diabetes. (4)
Dosing: Adult
- Hypertension (adults): 50 mg once daily; up to 100 mg once daily; 25 mg start if possible volume depletion (e.g., on diuretics)
- Hypertension with left ventricular hypertrophy: 50 mg once daily; add HCTZ 12.5 mg and/or increase to 100 mg, then HCTZ 25 mg as needed
- Diabetic nephropathy (type 2 diabetes): 50 mg once daily; increase to 100 mg once daily for blood pressure
- Hypertension Usual adult dose: 50 mg once daily. (2.1)
- Usual pediatric starting dose: 0.7 mg per kg once daily (up to 50 mg). (2.1)
- Hypertensive Patients with Left Ventricular Hypertrophy Usual starting dose: 50 mg once daily. (2.2)
- Add hydrochlorothiazide 12.5 mg and/or increase COZAAR to 100 mg followed by an increase to hydrochlorothiazide 25 mg if further blood pressure response is needed. (2.2, 14.2)
- Nephropathy in Type 2 Diabetic Patients Usual dose: 50 mg once daily. (2.3)
- Increase dose to 100 mg once daily if further blood pressure response is needed. (2.3)
2.1 Hypertension Adult
2.1 Hypertension Adult Hypertension The usual starting dose of COZAAR is 50 mg once daily. The dosage can be increased to a maximum dose of 100 mg once daily as needed to control blood pressure [see Clinical Studies (14.1)]. A starting dose of 25 mg is recommended for patients with possible intravascular depletion (e.g., on diuretic therapy).
Pediatric Hypertension The usual recommended starting dose is 0.7 mg per kg once daily (up to 50 mg total) administered as a tablet or a suspension [see Dosage and Administration (2.5)]. Dosage should be adjusted according to blood pressure response. Doses above 1.4 mg per kg (or in excess of 100 mg) daily have not been studied in pediatric patients [see Clinical Pharmacology (12.3), Clinical Studies (14.1), and Warnings and Precautions (5.2)].
COZAAR is not recommended in pediatric patients less than 6 years of age or in pediatric patients with estimated glomerular filtration rate less than 30 mL/min/1.73 m² [see Use in Specific Populations (8.4), Clinical Pharmacology (12.3), and Clinical Studies (14)].
2.2 Hypertensive Patients with Left Ventricular
2.2 Hypertensive Patients with Left Ventricular Hypertrophy The usual starting dose is 50 mg of COZAAR once daily. Hydrochlorothiazide 12.5 mg daily should be added and/or the dose of COZAAR should be increased to 100 mg once daily followed by an increase in hydrochlorothiazide to 25 mg once daily based on blood pressure response [see Clinical Studies (14.2)].
2.3 Nephropathy in Type 2 Diabetic Patients
2.3 Nephropathy in Type 2 Diabetic Patients The usual starting dose is 50 mg once daily. The dose should be increased to 100 mg once daily based on blood pressure response [see Clinical Studies (14.3)].
2.4 Dosage Modifications in Patients with Hepatic Impairment
2.4 Dosage Modifications in Patients with Hepatic Impairment In patients with mild-to-moderate hepatic impairment the recommended starting dose of COZAAR is 25 mg once daily. COZAAR has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.8) and Clinical Pharmacology (12.3)].
2.5 Preparation of Suspension (for 200 mL of a 2.5 mg/mL suspension)
2.5 Preparation of Suspension (for 200 mL of a 2.5 mg/mL suspension) Add 10 mL of Purified Water USP to an 8 ounce (240 mL) amber polyethylene terephthalate (PET) bottle containing ten 50 mg COZAAR tablets. Immediately shake for at least 2 minutes. Let the concentrate stand for 1 hour and then shake for 1 minute to disperse the tablet contents.
Separately prepare a 50/50 volumetric mixture of Ora-Plus ™ and Ora-Sweet SF ™. Add 190 mL of the 50/50 Ora-Plus ™ /Ora-Sweet SF ™ mixture to the tablet and water slurry in the PET bottle and shake for 1 minute to disperse the ingredients. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 4 weeks.
Shake the suspension prior to each use and return promptly to the refrigerator.
Dosing: Altered kidney function
Losartan, an angiotensin II receptor blocker (ARB), needs no dose change for kidney impairment alone per the US label, unless the patient is also volume depleted. Neither losartan nor its active metabolite is removed by hemodialysis.
Kidney function measure: Label PK uses creatinine clearance (CrCl); dosing statement is not band-specific.
Show full dosing details
- eGFR ≥60
- Usual dosing: 50 mg once daily, up to 100 mg once daily.
- eGFR 30–59
- No adjustment unless volume depleted (label). Exposure is 50 to 90% higher in mild to moderate impairment.
- eGFR 15–29
- No adjustment unless volume depleted (label). Monitor potassium and creatinine.
- eGFR <15 (not on dialysis)
- No label adjustment; monitor potassium, creatinine and blood pressure closely.
- Hemodialysis (intermittent)
- No adjustment in the label; not removed by hemodialysis.
- Peritoneal dialysis
- No label adjustment; no PD data.
- CRRT
- No data in label.
- Dialyzable? No: neither losartan nor its active metabolite is removed by hemodialysis (label).
- Monitoring Serum creatinine and potassium 2 to 4 weeks after starting or changing the dose; a creatinine rise up to 30% is expected and is not a reason to stop. Correct volume depletion before starting (label). KDIGO 2024 supports continuing the ARB when eGFR falls below 30.
Children (kidney dosing)
Show full dosing details
- eGFR ≥60
- Usual pediatric dose.
- eGFR 30–59
- Usual pediatric dose (no label adjustment); monitor potassium and creatinine.
- eGFR 15–29
- Not recommended: GFR <30 mL/min/1.73 m2 (label).
- eGFR <15 (not on dialysis)
- Not recommended (label).
- Hemodialysis (intermittent)
- Not recommended (GFR <30).
- Peritoneal dialysis
- Not recommended (GFR <30).
- CRRT
- Not recommended.
Pediatric eGFR: bedside Schwartz equation, 0.413 × height (cm) / serum creatinine (mg/dL). Weight-based doses should not exceed the adult maximum.
renalcarematters.com guidance, reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Sources are listed under References. Use with the product's package insert and the patient's current kidney function.
US label text: Renal impairment US FDA label
8.7 Renal Impairment Patients with renal insufficiency have elevated plasma concentrations of losartan and its active metabolite compared to subjects with normal renal function. No dose adjustment is necessary in patients with renal impairment unless a patient with renal impairment is also volume depleted [see Dosage and Administration (2.3), Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)].
Renal Insufficiency: Following oral administration, plasma concentrations and AUCs of losartan and its active metabolite are increased by 50-90% in patients with mild (creatinine clearance of 50 to 74 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal insufficiency. In this study, renal clearance was reduced by 55-85% for both losartan and its active metabolite in patients with mild or moderate renal insufficiency. Neither losartan nor its active metabolite can be removed by hemodialysis [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)].
Dosing: Hepatic impairment
8.8 Hepatic Impairment The recommended starting dose of COZAAR is 25 mg in patients with mild-to-moderate hepatic impairment. Following oral administration in patients with mild-to-moderate hepatic impairment, plasma concentrations of losartan and its active metabolite were, respectively, 5 times and 1.7 times those seen in healthy volunteers. COZAAR has not been studied in patients with severe hepatic impairment [see Dosage and Administration (2.4) and Clinical Pharmacology (12.3)].
2.4 Dosage Modifications in Patients with Hepatic Impairment In patients with mild-to-moderate hepatic impairment the recommended starting dose of COZAAR is 25 mg once daily. COZAAR has not been studied in patients with severe hepatic impairment [see Use in Specific Populations (8.8) and Clinical Pharmacology (12.3)].
US FDA labelDosing: Pediatric
- Approved ages
- Hypertension, 6 to 16 years (label). Not established under 6 years or with GFR <30 mL/min/1.73 m2.
- Usual dose
- 0.7 mg/kg once daily (up to 50 mg); doses above 1.4 mg/kg (or above 100 mg) daily have not been studied (label).
- Maximum dose
- 1.4 mg/kg/day, not to exceed 100 mg/day (studied range per label).
- Neonates
- Neonates: not recommended (under 6 years). In utero exposure: support blood pressure and renal perfusion if oliguria or hypotension.
Kidney dosing in children: see Dosing: Altered kidney function.
renalcarematters.com, reviewedPediatric use (US label) US FDA label
8.4 Pediatric Use Antihypertensive effects of COZAAR have been established in hypertensive pediatric patients aged 6 to 16 years. Safety and effectiveness have not been established in pediatric patients under the age of 6 or in pediatric patients with glomerular filtration rate <30 mL/min/1.73 m² [see Dosage and Administration (2.1), Clinical Pharmacology (12.3), and Clinical Studies (14.1)].
Dosing: Older adult
Geriatric use (US label) US FDA label
8.5 Geriatric Use Of the total number of patients receiving COZAAR in controlled clinical studies for hypertension, 391 patients (19%) were 65 years and over, while 37 patients (2%) were 75 years and over. In a controlled clinical study for renal protection in type 2 diabetic patients with proteinuria, 248 patients (33%) were 65 years and over.
In a controlled clinical study for the reduction in the combined risk of cardiovascular death, stroke and myocardial infarction in hypertensive patients with left ventricular hypertrophy, 2857 patients (62%) were 65 years and over, while 808 patients (18%) were 75 years and over. No overall differences in effectiveness or safety were observed between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.
Administration
2.5 Preparation of Suspension (for 200 mL of a 2.5 mg/mL suspension) Add 10 mL of Purified Water USP to an 8 ounce (240 mL) amber polyethylene terephthalate (PET) bottle containing ten 50 mg COZAAR tablets. Immediately shake for at least 2 minutes. Let the concentrate stand for 1 hour and then shake for 1 minute to disperse the tablet contents. Separately prepare a 50/50 volumetric mixture of Ora-Plus ™ and Ora-Sweet SF ™ . Add 190 mL of the 50/50 Ora-Plus ™ /Ora-Sweet SF ™ mixture to the tablet and water slurry in the PET bottle and shake for 1 minute to disperse the ingredients. The suspension should be refrigerated at 2-8°C (36-46°F) and can be stored for up to 4 weeks. Shake the suspension prior to each use and return promptly to the refrigerator.
US FDA labelDosage forms
Philippines
- Film-coated tablet: 50 mg, 100 mg, 500 mg
- Tablet: 50 mg, 100 mg
Registered products in the Philippines
375 products registered with the Food and Drug Administration (FDA) Philippines list Losartan as the generic name (including products registered under a variant spelling). Registration status changes; confirm a product's current status on the FDA portal before relying on it.
Also registered under: Losartan Potassiumn (1 product). Products registered under these spellings are included in the table and marked.
All registered products375
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
A.R.ALosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's packed in individual boxes (Box of 100’s) | RxVAT-exempt | Zim Laboratories LimitedIndia | Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-906 | Apr 22, 2028 | |
AmlopressLosartan potassium | 50 mg Film-Coated TabletAlu/ PVC/ PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Maraki Pharma Co.Importer: Amb Hk Enterprises Inc. | DRP-8522-08 | Oct 25, 2029 | |
AndrezarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Carl Andre Trading CorporationImporter: Medinova Pharmaceutical Inc. | DRP-8985-12 | Jul 21, 2030 | |
Andrezar-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Carl Andre Trading CorporationImporter: Medinova Pharmaceutical Inc. | DRP-8985-14 | Jul 21, 2030 | |
Angel-100Losartan potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Healer's Lab (Unit II)India | Pharmakon Biotec Inc. | DRP-12727 | Sep 28, 2027 | |
AngiceeLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | CDMed Pharmaceutical and Medical SupplyImporter: Pharmakon Biotec Inc. | DRP-13687-15 | Mar 28, 2028 | |
AngiiblocLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Day to Day Pharmacy | DRP-12412-14 | Sep 19, 2031 | |
AngiolorLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Medirich Pharma Distribution Corp.Trader: Eadriex Pharmaceuticals, Phils., Inc. | DRP-2635 | Nov 26, 2029 | |
AngiotenLosartan (as Potassium) | 100 mg TabletAlu/Red PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | — | DRP-7208 | Sep 4, 2030 | |
AngiotenLosartan Potassium | 50 mg TabletAlu/Red PVC Blister pack x 20's (Box of 100's); Alu/Red PVC Blister pack x 10's (Box of 30's )(For DOH USE only) | RxVAT-exempt | Drugmaker's Laboratories Inc.Philippines | — | DRP-7209 | Sep 2, 2030 | |
AngisartanLosartan potassium | 50 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd. | DRP-14267 | Jun 30, 2028 | |
AngisartanLosartan Potassium | 50 mg Film-Coated tabletBlister Pack x 10's (Box of 100's); Blister Pack x 14's (Box of 140's); Blister Pack x 10's (Box of 30's) [For DOH Use Only] | RxVAT-exempt | Plethico Pharmaceuticals Ltd.India | I.E. Medica, Inc.Trader: Wiscon Pharmaceuticals Pvt. Ltd. | DRP-996 | Nov 12, 2027 | |
AngisartanLosartan Potassium | 50mg Film-Coated TabletsAlu/PVC Blister pack x 10's (Box of 100' s) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd. | DR-XY48796 | Jun 30, 2028 | |
Angisartan-50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private Limitedindia | I.E. Medica, Inc. | DRP-17573 | Feb 2, 2028 | |
Anin 50Losartan Potassium | 50 mg Film-Coated TabletAlu-PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Delta Pharma Ltd.Bangladesh | Biomed Pharma Inc. | DR-XY39746 | Jul 11, 2031 | |
AntanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's). | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Orange Biotec Inc. | DRP-15448 | Jul 10, 2029 | |
AntorebLosartan Potassium | 100 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | ECE Pharmaceuticals, Inc.Importer: Nelpa Lifesciences Inc. | DRP-12531-01 | Sep 2, 2027 | |
AntorebLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Innovative HealthcareIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-18346 | Jun 18, 2031 | |
AntorebLosartan Potassium | 50 mg Film-coated TabletAlu/Alu Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | ECE Pharmaceutical,Inc.Importer: Nelpa Lifesciences Inc. | DRP-12532-01 | Sep 2, 2027 | |
AntorebLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Innovative HealthcareIndia | ECE Pharmaceuticals, Inc.Importer: Biophil Medical Equipment and Supplies Trading | DRP-18347 | Jun 18, 2031 | |
AnzarLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 30's) | RxVAT-exempt | MEDISURE LABORATORIES PAKISTAN (PVT) LTDPakistan | ADP PHARMA CORPORATIONImporter: STANGEN PHARMACEUTICALS PHILIPPINES INC | DRP-4775 | Oct 3, 2029 | |
AnzarLosartan Potassium | 50 mg TabletAlu/Alu Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | MICRO LABS LIMITEDIndia | ADP PHARMA CORPORATIONImporter: BROWN & BURK PHILS., INC. | DRP-897-01 | Oct 22, 2029 | |
ArbcureLosartan Potassium | 50 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmacure Medical Supplies TradingImporter: Pharmakon Biotec Inc. | DRP-13687-22 | Mar 28, 2028 | |
Arbisar-100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8523-01 | Oct 25, 2029 | |
Arbisar-50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8522-01 | Oct 25, 2029 | |
ArblocLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10’s (Box of 30’s, 50’s and 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | The Cathay YSS Distributors Co., Inc. | DRP-1667-07 | Mar 12, 2037 | |
ArblocLosartan Potassium | 50 mg Film-Coated TabletFoil Strip x 10's (Box of 30's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: The Cathay YSS Distributors Company, Inc. | DR-XY34525 | Feb 1, 2027 | |
ArblocLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | The Cathay YSS Distributors Co., Inc. | DRP-128-10 | Oct 10, 2030 | |
ArtalLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | Qualifirst Health Inc.Importer: Aglobal Care, Inc. | DRP-8058 | Apr 29, 2031 | |
Arteva 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-04 | Mar 28, 2028 | |
Arteva 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-05 | Mar 28, 2028 | |
Articure 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-02 | Mar 28, 2028 | |
Articure 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-02 | Mar 28, 2028 | |
Artosar 50Losartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Zest PharmaIndia | Sahar International Trading, Inc.Trader: NGB Laboratories Pvt. Ltd. | DR-XY43661 | Nov 19, 2030 | |
Artrice 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-03 | Mar 28, 2028 | |
Artrice 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-03 | Mar 28, 2028 | |
AzartanLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100;s) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | — | DRP-15663 | Aug 16, 2029 | |
AzartanLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | — | DRP-12412 | Aug 3, 2031 | |
BaczartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | JJYSRINN Trading Inc.Importer: Ambica International Corporation | DRP-12057-01 | Jun 3, 2027 | |
BaczartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 60's and 100's) | RxVAT-exempt | Windlas Biotech Limited (Plant-1)India | JJYSRINN Trading Inc.Importer: Ambica International CorporationTrader: Mankind Pharma Ltd. | DRP-5960-01 | Feb 4, 2028 | |
Bastisartan 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India 174101 | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-13 | Mar 28, 2028 | |
BepsarLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack X 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | EuroAsia Pharmaceuticals, IncTrader: Tunic Healthcare | DR-XY44643 | Jun 17, 2030 | |
BepsarLosartan Potassium | 50 mg TabletFoil Strip x 10’s (Box of 30’s) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Div. of J.B. Chemicals and Pharmaceuticals Limited)India | Euroasia Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-841-05 | May 4, 2027 | |
Bepsar-100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | EuroAsia Pharmaceuticals, Inc.Trader: Tunic Healthcare | DRP-14504 | Sep 15, 2028 | |
BesartanLosartan Potassium | 50 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Berlin Pharmaceutical Industry Co., Ltd.Thailand | Littman Drug CorporationImporter: Paradigm Pharma (Philippines) CorporationTrader: Paradigm Pharma (Thailand) Co., Ltd. | DRP-13778-01 | Feb 18, 2029 | |
BesartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 100's | RxVAT-exempt | Torrent Pharmaceuticals Ltd.India | Littman Drug CorporationImporter: Torrent Pharma Philippines, Inc. | DRP-2845-01 | Jul 24, 2027 | |
BesartanLosartan Potassium | 50 mg Film-Coated TabletWhite Opaque PVC/Alu/Alu Blister Pack x 14's (Box of 28's); White Opaque PVC/Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ipca Laboratories LimitedIndia | Littman Drug CorporationImporter: Blue Global (FZE) | DRP-3971-03 | Mar 15, 2030 | |
BesartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Littman Drug CorporationTrader: Totalcare Pharma Inc. | DRP-982-03 | May 28, 2027 | |
BesartanLosartan Potassium | 50 mg TabletFoil Strip x 10’s (Box of 100’s) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | Diafarm Inc.Importer: Ambica International Corporation | DRP-841-03 | May 4, 2027 | |
Biozart 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13686 | Mar 28, 2028 | |
Biozart 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Pharmakon Biotec Inc. | DRP-13687 | Mar 28, 2028 | |
BPbestLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | TGIF Pharmaceutical Trading Inc.Importer: Ambica International Corporation | DRP-2591-07 | Jul 31, 2028 | |
Cardiollen-100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s (Box of 30’s); Alu/PVC Blister Pack x 10’s Box of 60’s; Alu/PVC Blister Pack x 10’s Box of 90’s; Alu/PVC Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Sai Parenterals Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10666-01 | Apr 2, 2030 | |
Cardiollen-50Losartan Potassium | 50 mg Film-Coated TabletAlu / PVC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Sai Parenterals Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc. | DRP-10667-02 | Jan 30, 2030 | |
CardizarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Solvang Pharmaceuticals, Inc.Trader: Totalcare Pharma Inc. | DRP-982-02 | May 28, 2027 | |
CongezarLosartan Potassium | 50 mg Film-Coated Tablet. Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic Laboratories.India | AGB Pharmaceutical Trading and ConsultancyImporter: Ambica International Corporation | DRP-2591-04 | Jul 31, 2028 | |
CordizarLosartan Potassium | 50 mg Film-Coated TablerAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | D and JB Pharma Medica Corp.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1216-01 | Jul 30, 2028 | |
CotenaceLosartan Potassium | 50 mg Film-Coated TabletBlister Pack x 10's Box of 100's | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Hexagon Pharmaceuticals | DRP-722 | Oct 8, 2027 | |
CozaarLosartan potassium | 100mg TabletOpaque PVC/PE/PVDC blister pack x l0's (Box of 30's) | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Organon (Philippines) Incorporated | DRP-6250 | Dec 10, 2027 | |
COZAARLosartan Potassium | 50 mg TabletOpaque, White Alu/PE/PVC/PVDC Blister Pack x 10's Box of 30's | RxVAT-exempt | Organon Pharma (UK) LimitedUnited Kingdom | Importer: Organon (Philippines) Incorporated | DRP-6249 | Mar 24, 2029 | |
CozalynLosartan Potassium | 50 mg Film-coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | Vitalife Pharma & Medical Supply Inc.Importer: I.E. Medica, Inc. | DRP-8657-03 | Jan 31, 2030 | |
Cozalyn 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Dagon Pharmaceuticals Pvt. Ltd.India | Vitalife Pharma & Medical Supply Inc.Importer: Philgen Pharmaceuticals Inc. | DRP-15133-01 | May 8, 2029 | |
CuresartanLosartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-6453-03 | Nov 27, 2030 | |
Curesartan 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Diafarm Inc.Importer: Ambica International Corporation | DRP-4693-12 | Sep 6, 2028 | |
Diassium 50Losartan (as Potassium) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-3183-04 | Jun 7, 2032 | |
DoxarLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: PNSV ASIA CORPORATION | DR-XY35051 | Oct 16, 2028 | |
Dylaran-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Better Option Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4693-01 | Sep 6, 2028 | |
EbatanLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-12412-04 | Sep 19, 2031 | |
EkosartLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Ticaret A.S.Turkey | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-2184-01 | Jul 7, 2029 | |
EkosartLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Tiracet A.S. (Gebze 2)Turkey | TGP Pharma Inc.Importer: Sandoz Philippines Corporation | DRP-2183-01 | Jan 26, 2030 | |
EpisartanLosartan Potassium | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 30’s; Box of 60's and Box of 100's) | RxVAT-exempt | Kopran LimitedIndia | Epione Lifecare Inc.Importer: Despina Pharma Inc. | DRP-13056-02 | Nov 23, 2027 | |
FersartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Ferma Drug EnterprisesImporter: Pharmakon Biotec Inc. | DRP-13687-19 | Mar 28, 2028 | |
FisartanLosartan Potassium | 100 mg Film-Coated TabletPVC Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories Inc.Philippines | Firstmed Theraconcept Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1100-08 | Dec 17, 2030 | |
FISARTANLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | FIRSTMED THERACONCEPT INC.Trader: INTERHEALTHCARE PHARMACEUTICAL INC. | DRP-1216-08 | Jul 30, 2028 | |
Fixtasart-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Private LimitedIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-07 | May 26, 2028 | |
FlosartanLosartan Potassium | 50 mg Film-Coated TabletAluminum Strip Foil x 10's (Box of 30's); Aluminum Strip Foil x 10's (Box of 100's) | RxVAT-exempt | Bauch Phils. Laboratories Corp.Philippines | Lo-Ar Pharmaceutical Co., Inc. | DRP-4884 | Oct 31, 2028 | |
GensartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc. | DRP-8985-02 | Aug 6, 2031 | |
Gensartan 100Losartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | Skymed Pharma DistributorImporter: Medinova Pharmaceutical Inc. | DRP-16506-03 | Apr 2, 2030 | |
GenzarLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Eba Generisch Trading Inc. | DRP-12412-03 | Jul 14, 2031 | |
GetzarLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10’s (Box of 50’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Getz Pharma (Phils.), Inc. | DRP-1667-02 | Aug 11, 2030 | |
GetzarLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Getz Pharma (Phils.), Inc. | DRP-128-04 | Oct 10, 2030 | |
Gisart 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Gijun Trading Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8985-03 | Aug 6, 2031 | |
Gosartan-100 ExtraLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-4693-09 | Sep 6, 2028 | |
Gowin 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4693-03 | Sep 6, 2028 | |
Goztan 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Synmedic LaboratoriesIndia | Applied Pharmaceutical Distribution Inc.Importer: Ambica International Corporation | DRP-2591-09 | Jul 31, 2028 | |
Goztan 50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Applied Pharmaceutical Distribution Inc.Importer: AMB HK Enterprises Inc. | DRP-8522-09 | Oct 25, 2029 | |
Goztan-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Applied Pharmaceutical Distribution Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8985-07 | Jul 21, 2030 | |
GrosartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | J. Duncan Healthcare Pvt. Ltd.India | Grovic Pharma, Inc. | DRP-7302 | Apr 5, 2031 | |
HartzarLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Pharma Dynamic, Inc. | DRP-128-05 | Oct 10, 2030 | |
HextanLosartan Potassium | 50 mg Film-Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Trumed PharmaceuticalsImporter: Hexagon Pharmaceuticals | DRP-722-03 | Oct 8, 2027 | |
HizarLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals, Inc. | DRP-1882-04 | Mar 4, 2027 | |
HizarLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Harlem SalesImporter: Philgen Pharmaceuticals Inc. | DRP-1884-04 | Sep 14, 2027 | |
HypertanLosartan Potassium | 100 mg Film-Coated TabletPVC Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmceuticals Inc. | DRP-1100 | Dec 17, 2029 | |
HypertanLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | TGP Pharma Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1216 | Jul 30, 2028 | |
HyperthreeLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | One Pharma Marketing Inc. | DRP-128-02 | Oct 10, 2030 | |
JensarLosartan Potassium | 50 mg TabletFoil Strip x 10’s (Box of 100’s) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals LimitedIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-841-01 | May 4, 2027 | |
JiaazarLosartan Potassium | 50 mg Film-Coated TabletAlu / PVC / PVDC Blister Pack x 10’s (Box of 30’s & Box of 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Jiaa PharmaImporter: AMB HK Enterprises Inc. | DRP-8522-06 | Oct 25, 2029 | |
JisartanLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's packed in individual boxes (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Jiaa PharmaImporter: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-906-07 | Apr 22, 2028 | |
Jysartan 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Zim Laboratories LimitedIndia | Jjysrinn Trading Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-906-06 | Apr 22, 2028 | |
KardiostanLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | — | DRP-1454 | Feb 20, 2029 | |
KardiostanLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's as Physician sample (Box of 10's); Alu/Clear PVC Blister Pack x 2's as Physician sample (Box of 2's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | — | DRP-1456 | Mar 19, 2029 | |
KenzarLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-5934 | Dec 3, 2028 | |
KenzarLosartan (as Potassium) | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | The ACME Laboratories LimitedBangladesh | Bell-Kenz Pharma Inc.Importer: Euro Generics International Phils., Inc. | DRP-2215 | Jan 3, 2032 | |
KhrizaacLosartan Potassium | 50mg TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Merit Organics Ltd.India | Khriz Pharma Trading Inc. | DRP-18978 | Oct 12, 2031 | |
KodisarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | Kodi Biosciences Inc.Importer: Aglobal Care, Inc. | DRP-8058-06 | Apr 29, 2031 | |
Kodisar 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kodi Biosciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-11 | Mar 28, 2028 | |
KozartanLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's,50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Konzept Convenience And Drug Store Corp. | DRP-12412-06 | Aug 1, 2031 | |
Ksart 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC/PVDC Blister Pack x 10's (Box of 30's and 50's) | RxVAT-exempt | KUSUM HEALTHCARE PRIVATE LIMITEDIndia | KUSUM HEALTHCARE PRIVATE LIMITED BRANCH OFFICE | DR-XY39984 | Sep 1, 2027 | |
L-ZerprimeLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Life and Health Source Pharmaceutical Distribution Co.Importer: Pharmakon Biotec Inc. | DRP-13687-09 | Mar 28, 2028 | |
Lanzaar 50Losartan Potassium | 50 mg Film-Coated TabletAlu/White PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Berlin Pharmaceutical Industry Co., Ltd.Thailand | Metro Drug, Inc.Importer: Paradigm Pharma (Philippines) CorporationTrader: Paradigm Pharma (Thailand) Co., Ltd. | DRP-13778 | Feb 18, 2029 | |
LeesartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | C & S Medical Solutions Inc.Importer: Aglobal Care, Inc. | DRP-8058-07 | Feb 4, 2032 | |
Leesartan 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | C & S Medical Solutions Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-08 | Mar 28, 2028 | |
LexzarLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Auspicia Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1216-10 | Jul 30, 2028 | |
LifetanLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Life and Health Source Pharmaceutical Distribution Co.Importer: Medinova Pharmaceutical Inc. | DRP-8985-06 | Aug 6, 2031 | |
LifezarLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Ticaret A.S.Turkey | Unilab, Inc.Importer: Sandoz Philippines Corporation | DRP-2184-03 | Jul 7, 2029 | |
LifezarLosartan Potassium | 100 mg TabletWhite Opaque Aluminum Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-2676 | Jun 6, 2027 | |
LifezarLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's and 15's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Tiracet A.S. (Gebze 2)Turkey | UNILAB, Inc.Importer: Sandoz Philippines Corporation | DRP-2183-03 | Jan 26, 2030 | |
LifezarLosartan Potassium | 50 mg TabletWhite Opaque Aluminum Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Trader: UNILAB, Inc. | DRP-2675 | Jun 6, 2027 | |
LipewinLosartan (as Potassium) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Applied Pharmaceutical DistributionImporter: Ambica International Corporation | DRP-3183 | Jun 7, 2037 | |
LO-KLosartan Potassium | 50mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc. | DRP-16832 | Jul 16, 2030 | |
LodeesartLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 60's and 100's) | RxVAT-exempt | Windlas Biotech Limited (Plant-1)India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Mankind Pharma Ltd. | DRP-5960-03 | Feb 4, 2028 | |
LorcareLosartan Potassium | 100 mg Film-Coated TabletAlu / Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Jaac Healthline Marketing | DRP-15663-04 | Aug 16, 2029 | |
LorcareLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Jaac Healthline Marketing | DRP-12412-13 | Jul 14, 2031 | |
LortanLosartan Potassium | 50 mg TabletAlu-Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Biopharma Laboratories LimitedBangladesh | JF Draf Pharmaceuticals Corporation | DRP-3306 | Oct 12, 2031 | |
LortavonLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15663-06 | Aug 16, 2029 | |
LortavonLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12412-16 | Aug 3, 2031 | |
Losa Speed 100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Speed Med Pharmaceuticals Inc. | DRP-1454-07 | Feb 20, 2029 | |
Losaar 100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises, Inc. | DRP-8523 | Oct 25, 2029 | |
Losaar 50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | AMB HK Enterprises Inc. | DRP-8522 | Oct 25, 2029 | |
LosablocLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-5458-01 | Aug 18, 2029 | |
LosacarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 7's (Box of 70's) | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-1230 | Jan 30, 2028 | |
Losacar 100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVDC/PVC Blister Pack x 10's (Box of 100's); Alu/PVDC/PVC Blister Pack x 10's (Box of 10's as Physician's Sample) | RxVAT-exempt | Cadila Healthcare LimitedIndia | Zydus Healthcare Philippines, Inc. | DRP-7348 | Feb 8, 2028 | |
Losacraft-50Losartan Potassium | 50 mg Film-coated tabletAlu/ Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | Ellebasy Medicale Group, Inc.Importer: I.E. Medica, Inc. | DRP-8657 | Jan 31, 2030 | |
LosacuraLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | RVM Pharma & Medical Supplies DistributionImporter: Orange Biotec Inc. | DRP-15448-04 | Jul 10, 2029 | |
LosafilLosartan Potassium | 50 mg Film-Coated TabletAlu/ PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Filadams Pharma, Inc.Trader: Interhealthcare Pharmaceuticals, Inc. | DRP-1216-12 | Jul 30, 2028 | |
Losagan-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-5458 | Aug 18, 2029 | |
Losagen 50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hetero Labs Limited (Unit V)India | Camber Pharmaceuticals, Inc. | DRP-6891 | Mar 11, 2027 | |
LosagetLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Hetero Labs Limited (Unit-V)India | 2MG IncorporatedImporter: Camber Pharmaceuticals, Inc. | DRP-6891-01 | Mar 11, 2027 | |
LosagoldLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Brilliantmeed, Inc. | DRP-15663-08 | Aug 16, 2029 | |
Losakind-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | Ambica International Corporation | DRP-12057 | Jun 3, 2032 | |
Losakind-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 60’s); Alu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Windlas Biotech Limited (Plant-1)India | Ambica International CorporationTrader: Mankind Pharma Ltd. | DRP-5960 | Feb 4, 2028 | |
Losamar-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-15663-05 | Aug 16, 2029 | |
LOSAMAR-50Losartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Triple 888 Medical And Pharma Inc. | DRP-12412-15 | Aug 3, 2031 | |
LosamaxLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Medicamen Biotech LimitedIndia | Pharmastar Int'l Trading Corp. | DRP-17425 | Dec 15, 2030 | |
Losan 50Losartan Potassium | 50mg TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Kopran LimitedIndia | Despina Pharma, Inc. | DRP-13056 | Nov 23, 2027 | |
Losangio 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's); Alu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Trader: Endurance Healthcare Ltd. | DRP-5188 | Oct 25, 2028 | |
LosaprimeLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-03 | May 26, 2028 | |
Losar-50Losartan potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Unichem Laboratories Limited (Unit II)India | Ambica International Corporation | DRP-4834 | Oct 18, 2028 | |
LosaramLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Federal Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-04 | May 26, 2028 | |
LosarbetLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-10 | Mar 28, 2028 | |
LosarcureLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Prodrom Nutritionals, IncorporatedImporter: Ambica International Corporation | DRP-4693-10 | Sep 6, 2028 | |
LosargardLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-6406 | May 30, 2027 | |
LosargardLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's Box of 30's | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Innogen Pharmaceuticals, Inc. | DRP-6407 | Jun 22, 2027 | |
LosarkLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | 777 Red Pharma Inc.Importer: Philgen Pharmaceuticals, Inc. | DRP-1882-03 | Mar 4, 2027 | |
Losarkip 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kipson Pharmaceutical TradingImporter: Pharmakon Biotec Inc. | DRP-13686-12 | Mar 28, 2028 | |
Losarkip 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kipson Pharmaceutical TradingImporter: Pharmakon Biotec Inc. | DRP-13687-16 | Mar 28, 2028 | |
LosarloLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Medibios Laboratories Pvt.Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-02 | May 26, 2028 | |
LosarnielLosartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Speed Cure PharmaImporter: Ambica International Corporation | DRP-6453-04 | Nov 27, 2030 | |
LosartLosartan Potassium | 50 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 100's and Box of 30's for DOH) | RxVAT-exempt | Concept Pharmaceuticals Ltd.India | Phil Pharmawealth, Inc. | DR-XY38577 | Oct 5, 2030 | |
LosartapLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15663-02 | Aug 16, 2029 | |
LosartapLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12412-01 | Aug 1, 2031 | |
LosartfixLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 60's and 100's) | RxVAT-exempt | Windlas Biotech Private Limited (Plant-1)India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International CorporationTrader: Mankind Pharma Ltd. | DRP-5960-04 | Feb 4, 2028 | |
Losartrixx 100Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8523-02 | Oct 25, 2029 | |
Losartrixx 50Losartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10’s Box of 30’s and 100’s | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | PhilRx Pharma Inc.Importer: AMB HK Enterprises Inc. | DRP-8522-02 | Oct 25, 2029 | |
Losarx 100Losartan Potassium | 100 mg Film-Coated TabletsAlu-Alu Blister Pack of 10's (Box of 100's). | RxVAT-exempt | Globela Pharma Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-15533 | Jul 31, 2029 | |
Losarx 100Losartan (as Potassium) | 100mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10 tablets (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13557 | Mar 9, 2028 | |
Losarx 50Losartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Globela Pharma Pvt. Ltd.India | AMB HK Enterprises Inc. | DRP-15534 | Jul 31, 2029 | |
Losarx 50Losartan (as Potassium) | 50mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10 tablets (Box of 10 blister packs x 10 tablets) | RxVAT-exempt | Globela Pharma Private LimitedIndia | Amb Hk Enterprises Inc.Importer: AMB HK Enterprises Inc. | DRP-13556 | Mar 9, 2028 | |
LosaSpeed 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's as Physician sample (Box of 10's); Alu/Clear PVC Blister Pack x 2's as Physician sample (Box of 2's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Speed Med Pharmaceuticals Inc. | DRP-1456-06 | Mar 19, 2029 | |
Losastal-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambica International Corporation | DRP-5040 | Jan 7, 2029 | |
LosaverLosartan Potassium | 50 mg Film-Coated TabletAlu / Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Rule Med Pharma Corp.Importer: Pharmakon Biotec Inc. | DRP-13687-12 | Mar 28, 2028 | |
Losawin-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-4693 | Sep 6, 2028 | |
Losawin-50Losartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambica International Corporation | DRP-6453 | Nov 27, 2030 | |
LosiumLosartan (as potassium) | 50 mg Film-Coated TabletAluminum Strip Foil x 10's Box of 100's | RxVAT-exempt | Cadila Pharmaceuticals Ltd.India | Ambica International Corporation | DRP-5733 | Mar 5, 2029 | |
LosmacLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 50’s and 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Trader: Mac Heal Laboratories Ltd. | DRP-3303 | Oct 11, 2031 | |
LossiutabLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-5040-05 | Jan 7, 2029 | |
LOSTANLosartan Potassium | 100 mg Film-Coated TabletPVC / ALU BLISTER PACK X 10'S (BOX OF 100'S) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | GOLD LIFE DISTRIBUTION PHILS. INC.Trader: INTERHEALTHCARE PHARMACEUTICALS INC. | DRP-1100-09 | Dec 17, 2029 | |
LostanLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | J.M. TOLMANN LABORATORIES INC.Philippines | GOLD LIFE DISTRIBUTION PHILS. INC.Trader: INTERHEALTHCARE PHARMACEUTICALS INC. | DRP-1216-11 | Jul 30, 2028 | |
LostarLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Zim Laboratories LimitedIndia | Starpharm, Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-906-01 | Apr 22, 2028 | |
Lostar 100Losartan Potassium | 100 mg Film-Coated TabletAlu / Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Starpharm, Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-05 | May 26, 2028 | |
Lostar-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Starpharm, Inc.Importer: Ambica International Corporation | DRP-4693-02 | Sep 6, 2028 | |
Lostar-50Losartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Starpharm, Inc. | DRP-12412-12 | Dec 13, 2031 | |
LotaseLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Randril International Co., Inc. | DR-XY33358 | May 23, 2027 | |
LotaseLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Randril International Co., Inc. | DRP-15625 | May 23, 2027 | |
LoxartLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Basic Pharmaceutical CorporationTrader: Interhealthcare Pharmaceuticals Inc. | DRP-1216-09 | Jul 30, 2028 | |
Loza 50Losartan Potassium | 50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | The Madras PharmaceuticalsIndia | Better Option Pharmaceuticals, IncImporter: Synergen Pharma Inc.Trader: Synergen Asia Pte. Ltd. | DRP-1767 | Feb 10, 2029 | |
LozaarLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Totalcare Pharma Inc. | DRP-982 | May 28, 2027 | |
LozakLosartan (as Potassium) | 100 mg TabletAlu/Amber PVC Blister Pack x 10's (Box of 30's); Alu/Amber PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LIFESQUARE LABORATORIES INCPhilippines | — | DRP-4724 | Sep 17, 2029 | |
LozakLosartan Potassium | 50 mg TabletAlu-White Opaque PVC Blister Pack x 10's Box of 30's and 100's (with blue packaging design/layout); Alu-White Opaque PVC Blister Pack x 10's Box of 30's (with green packaging design/layout with Philippine Government - "DOH Property Not for Sale") | RxVAT-exempt | LifeSquare Laboratories, Inc.Philippines | — | DRP-4706 | Sep 13, 2031 | |
Lozark 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30’s, 60’s, 90’s and 100’s) | RxVAT-exempt | Sai Parenterals LtdIndia | Roymed PharmaceuticalImporter: Nelpa Lifesciences, Inc. | DRP-12532-04 | Jan 23, 2031 | |
Lozart 50Losartan potassium | 50mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Despina Pharma Inc. | DRP-16743 | Jul 4, 2030 | |
Lozend 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-13686-06 | Mar 28, 2028 | |
Lozend 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Hale Medipoint Corp.Importer: Pharmakon Biotec Inc. | DRP-13687-06 | Mar 28, 2028 | |
LoztafixxLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-09 | May 26, 2028 | |
MabisartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Medconcern Drugs and General Merchandise Inc.Importer: Orange Biotec Inc. | DRP-15448-02 | Jul 10, 2029 | |
MalsarLosartan Potassium | 50 mg TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | PharmEvo (Pvt.) Ltd.Pakistan | Malyka International Trading Corp.Importer: Accesspoint International Trading Inc. | DRP-5768-01 | Dec 4, 2028 | |
MedzartLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY43008 | Nov 22, 2028 | |
MedzartLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Medhaus Pharma Inc. | DR-XY43007 | Nov 22, 2028 | |
MelsartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | RM Lorenzo Pharma & Distribution Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-14 | Mar 28, 2028 | |
MoxifastLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-4693-07 | Sep 6, 2028 | |
MyotanLosartan Potassium | 50 mg TabletFoil Strip x 10's (Box of 30's and 100's) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | JBCPL Philippines Inc. | DRP-841 | May 4, 2027 | |
MysartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Primera Pharma CorporationImporter: Ambica International Corporation | DRP-2591-03 | Jul 31, 2028 | |
MyzarLosartan (as Potassium) | 100 mg Film-Coated TabletPVC-PVDC-Alu Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Phil Pharmawealth, Inc.Importer: Singapore Genebio Inc. | DR-XY38637 | Oct 15, 2030 | |
MyzarLosartan (as Potassium) | 50 mg Film-coated TabletPVC-PVDC-Alu Blister Pack x 14's (Box of 28's) | RxVAT-exempt | Intas Pharmaceuticals LimitedIndia | Phil Pharmawealth, inc.Importer: Singapore Genebio, Inc. | DR-XY38638 | Oct 15, 2030 | |
NatrasolLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-1882 | Mar 4, 2027 | |
NatrasolLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's); Alu/Clear PVC Blister Pack x 10's (Box of 30's) [For DOH Use Only] | RxVAT-exempt | Centurion Laboratories Pvt. Ltd.India | Philgen Pharmaceuticals, Inc. | DRP-1884 | Sep 14, 2027 | |
Natrasol 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Dagon Pharmaceuticals Pvt. Ltd.India | Philgen Pharmaceuticals Inc. | DRP-15133 | May 8, 2029 | |
NatrazolLosartan Potassium | 100 mg TabletAlu/White Opaque PVC Blister Pack x 20's Box of 100’s; Alu/White Opaque PVC Blister Pack x 10's Box of 30’s [Property of Department of Health] | RxVAT-exempt | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7116 | Nov 13, 2027 | |
NatrazolLosartan Potassium | 50 mg TabletAlu/White Opaque PVC Blister Pack x 20's (Box of 100's); Alu/White Opaque PVC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Diamond Laboratories Inc.Philippines | Rilem Pharma Corp. | DRP-7115 | Nov 13, 2027 | |
NavsartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | JNC Pharmaceuticals CorporationImporter: Pharmakon Biotec, Inc. | DRP-13687-20 | Mar 28, 2028 | |
NeosartanLosartan Potassium | 100mg Film-Coated TabletAlu/Pvc Blister Pack X 10's (Box of 30's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY36844 | Oct 20, 2030 | |
NeosartanLosartan Potassium | 50 mg Film-Coated TabletAlu/White Pvc Blister Pack X 10's (Box of 30's and 300's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: GX International, Inc. | DR-XY37290 | Jan 4, 2030 | |
Neozart 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Neo Care Philippines, Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8985-13 | Jul 21, 2030 | |
NewsartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | New Seammed Inc.Importer: Medinova Pharmaceutical Inc. | DRP-8985-08 | Aug 18, 2031 | |
NexartLosartan (as Potassium) | 50mg TabletAlu/Red PVC Blister Pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories, Inc.Philippines | Chmi Pharma, Inc. | DRP-7209-02 | Sep 19, 2037 | |
NipartanLosartan Potassium | 50 mg TabletAlu/Alu Blister Pack x 10''s (Box of 30's and 100's) | RxVAT-exempt | Micro Labs LimitedIndia | Brown & Burk Philippines Inc. | DRP-897 | Oct 22, 2029 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Dyna Drug Corporation | DR-XY39433 | May 9, 2031 | |
NoneLosartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Sai Parenterals Ltd.#51 TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | PharmaVital Corp.Importer: Nelpa Lifesciences, Inc. | DRP-10666-02 | Apr 2, 2030 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletPVC Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | J.M. Tolmann Laboratories, Inc.Philippines | Gamot Philippines, Inc.Trader: Interhealthcare Pharmaceuticals Inc. | DRP-1100-07 | Dec 17, 2029 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-01 | Mar 28, 2028 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's Box of 10's and 100's | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1454-03 | Feb 20, 2029 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-1454-04 | Feb 20, 2029 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-1454-06 | Feb 20, 2029 | |
NoneLosartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical IncImporter: Medinova Pharmaceutical Inc. | DRP-16506-02 | Apr 2, 2030 | |
NoneLosartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | MED4UImporter: Medinova Pharmaceutical Inc. | DRP-16506-04 | Apr 2, 2030 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Actimed, Inc. | DRP-1667-08 | Feb 9, 2037 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu blister pack x 10’s (Box of 100’s) | RxVAT-exempt | Saga Lifesciences LimitedIndia | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-16773-01 | Dec 14, 2026 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's; Alu/PVC/PVDC Blister Pack x 15's Box of 30's | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilacari Sanayi Ve Tiracet A.S. (Gebze 2)Turkey | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-2184-02 | Jul 7, 2029 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Actimed, Inc.Importer: Ambica International Corporation | DRP-4693-04 | Sep 6, 2028 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Bewise Trading Corp. doing business under the name and style of Pharmaplus Generic & Branded Dug Distributor & Medical SuppliesImporter: Ambica International Corporation | DRP-4693-13 | Sep 6, 2028 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletOpaque White PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | — | DRP-5096 | Dec 7, 2030 | |
NoneLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Farmacia ni Dok, Inc.Importer: AMB HK Enterprises Inc. | DRP-8523-03 | Oct 25, 2029 | |
NONELosartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Actimed, Inc.Importer: AMB HK Enterprises Inc. | DRP-8523-05 | Oct 25, 2029 | |
NoneLosartan Potassium | 100 mg TabletWhite Opaque Aluminum Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-2676-02 | Jun 6, 2027 | |
NoneLosartan Potassium | 50 mg Film Coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Flamingo Pharmaceuticals Ltd.India | Qualifirst Health Inc.Importer: Hexagon Pharmaceuticals | DRP-722-04 | Oct 8, 2027 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Dyna Drug Corporation | DR-XY39432 | May 9, 2031 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Sai Parenterals Ltd.TSIIC Industrial Park Hyderabad-Warangal Highway Bhongir Telangana 508116 India | PharmaVital Corp.Importer: Nelpa Lifesciences, Inc. | DRP-12532-03 | Jan 23, 2031 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10’s (Box of 30’s, 50’s and 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-128 | Oct 10, 2030 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Zydus Healthcare Philippines Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-01 | Mar 28, 2028 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | —India | Alkem Laboratories CorporationImporter: Pharmakon Biotec Inc. | DRP-13687-11 | Mar 28, 2028 | |
NoneLosartan potassium | 50 mg Film-coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Novagen Healthcare Private LimitedIndia | Actimed, Inc.Importer: I.E. Medica, Inc.Trader: Plethico Laboratories Pvt. Ltd. | DRP-14267-01 | Jun 30, 2028 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Rose Pharmacy, Incorporated | DRP-1456-02 | Mar 19, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | Neodrug Inc. | DRP-1456-03 | Mar 19, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Better Option Pharmaceuticals, Inc.Importer: Orange Biotec Inc. | DRP-15448-03 | Jul 10, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack of 10's (Box of 30's); Alu-Alu Blister Pack of 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Miracare CorporationImporter: Teramedix Pharma Trading Inc. | DRP-16161-01 | Dec 4, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10’s (Box of 30’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Cyden Medicale Trading Inc.Importer: Teramedix Pharma Trading Inc. | DRP-16161-04 | Dec 4, 2029 | |
NoneLosartan Potassium | 50 mg FIlm-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's); Alu/PVC/PVDC Blister Pack x 15's (Box of 30's) | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Tiracet A.S. (Gebze 2)Turkey | Ritemed Phils., Inc.Importer: Sandoz Philippines Corporation | DRP-2183-02 | Jan 26, 2030 | |
NoneLosartan (as Potassium) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Actimed, Inc.Importer: Ambica International Corporation | DRP-3183-02 | Jun 7, 2027 | |
NoneLosartan (as Potassium) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ritemed Phils., Inc.Importer: Ambica International Corporation | DRP-3183-05 | Jun 7, 2027 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletWhite Opaque PVC/Alu/Alu Blister Pack of 14's (Box of 28's) | RxVAT-exempt | IPCA Laboratories LimitedIndia | International Pharmaceuticals, Inc.Importer: Blue Global (FZE) | DRP-3971-02 | Mar 15, 2030 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Ambica International Corporation | DRP-5040-06 | Jan 7, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletOpaque white PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | — | DRP-5095 | Dec 7, 2030 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletOpaque white PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Watsons Personal Care Stores (Philippines), Inc. | DRP-5095-01 | Feb 7, 2032 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletOpaque white PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Ritemed Phils., Inc. | DRP-5095-03 | Feb 3, 2032 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | AGB Pharmaceutical Trading and Consultancy CorporationImporter: Diafarm Inc.Trader: Endurance Healthcare Ltd. | DRP-5188-01 | Oct 25, 2028 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Boie Incorporated | DRP-5916-01 | Dec 23, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletPVC/PVDC Film-Blister x 10’s (Box of 30’s) | RxVAT-exempt | Agio Pharmaceuticals LimitedIndia | Providencia Medica, Inc.Importer: Ambica International Corporation | DRP-6409 | May 13, 2031 | |
NoneLosartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6453-01 | Apr 1, 2037 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Airlife International Trading CorporationImporter: Ambica International Corporation | DRP-6453-06 | Nov 27, 2030 | |
NoneLosartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Bewise Trading Corp. Doing business under the name & style of Pharmaplus Generic & Branded Drug Distributor & Medical SuppliesImporter: Ambica International Corporation | DRP-6453-07 | Nov 27, 2030 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Farmacia ni Dok, Inc.Importer: AMB HK Enterprises Inc. | DRP-8522-04 | Oct 25, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's Box of 30's and 100's | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Dyna Drug CorporationImporter: AMB HK Enterprises Inc. | DRP-8522-05 | Oct 25, 2029 | |
NoneLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | MED4UImporter: Medinova Pharmaceutical Inc. | DRP-8989-15 | Jul 21, 2030 | |
NoneLosartan Potassium | 50 mg Film-coated tabletBlister pack x 10's (Box of 100's) | RxVAT-exempt | Plethico Pharmaceuticals Ltd.India | Actimed, Inc.Importer: I.E. Medica, Inc.Trader: Wiscon Pharmaceuticals Ltd. | DRP-996-03 | Nov 12, 2027 | |
NoneLosartan Potassium | 50 mg TabletWhite Opaque Aluminum Blister Pack x 10's (Box of 50's) | RxVAT-exempt | Amherst Laboratories, Inc.Philippines | Ritemed Phils., Inc.Trader: UNILAB, Inc. | DRP-2675-02 | Jun 6, 2027 | |
NoneLosartan (as Potassium) | 50 mg TabletAlu/Red PVC Blister pack x 20's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories IncPhilippines | TGP Pharma Inc. | DRP-7209-01 | Sep 17, 2031 | |
NoneLosartan Potassium | 50 mg TabletFoil Strip x 10’s (Box of 100’s) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals and Pharmaceuticals Limited)India | Actimed, Inc.Importer: Ambica International Corporation | DRP-841-04 | May 4, 2027 | |
NovasartanLosartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private Limited.India | Medinova Pharmaceutical Inc | DRP-16506 | Apr 2, 2030 | |
NovasartanLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnaris Pharmaceuticals Private LimitedIndia | Medinova Pharmaceutical Inc. | DRP-18965 | Oct 8, 2031 | |
NovasartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Medinova Pharmaceutical Inc. | DRP-8985 | Jul 21, 2030 | |
OranzarLosartan Potassium | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 100’s) | RxVAT-exempt | Zim Laboratories LimitedIndia | Orange Biotec Inc.Importer: Suhitas Pharmaceuticals Inc.Trader: PSA International (Export Division of PSA Chemicals & Pharmaceuticals Pvt. Ltd.) | DRP-906-05 | Apr 22, 2028 | |
Parten-50Losartan Potassium | 50 mg TabletAlu-clear PVC Blister Pack x 10’s (Box of 1's) | RxVAT-exempt | JAYSON PHARMACEUTICALS LTD.Bangladesh | AGLOBAL CARE, INC. | DRP-4635 | Feb 1, 2028 | |
PillsartLosartan Potassium | 100 mg Film-Coated TabletAlu/ Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-06 | May 26, 2028 | |
PotazarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | D'Conner PharmaImporter: Pharmakon Biotec Inc. | DRP-13687-10 | Mar 28, 2028 | |
Presartan-100Losartan Potassium | 100 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 14's (Box of 28's); Alu/White Opaque PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Ipca Laboratories LimitedIndia | Blue Global (FZE) | DRP-3902 | Sep 7, 2031 | |
Presartan-50Losartan Potassium | 50 mg Film-Coated TabletWhite Opaque PVC/Alu/Alu Blister Pack of 14's (Box of 28's); White Opaque PVC/Alu/Alu Blister Pack of 10's (Box of 30's and 100's) | RxVAT-exempt | Ipca Laboratories LimitedIndia | Blue Global (FZE) | DRP-3971 | Mar 15, 2030 | |
PrestanLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's Box of 30's, 50's, and 100's | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Actimed, Inc. | DRP-1667 | Aug 11, 2030 | |
PrestanLosartan potassium | 50 mg Film-Coated TabletAlu-White PVC/PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | — | DRP-15156 | May 15, 2029 | |
PrestanLosartan Potassium | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Actimed, Inc. | DRP-5916 | Dec 23, 2029 | |
ProlostanLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Chempro Pharma Private LimitedIndia | Jjysrinn Trading Inc.Importer: Ambica International Corporation | DRP-10067 | May 26, 2028 | |
ProvizarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Providencia Medica Inc.Importer: Ambica International Corporation | DRP-5040-07 | Jan 7, 2029 | |
ProzartLosartan Potassium | 50 mg TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lark Laboratories (India) Ltd.India | D&G Pharma | DR-XY36955 | Nov 10, 2030 | |
Prozart 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100’s) | RxVAT-exempt | Synmedic LaboratoriesIndia | D&G PharmaImporter: Ambica International Corporation | DRP-2591-08 | Jul 31, 2028 | |
Q-PidLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-2591-05 | Jul 31, 2028 | |
Q-PidLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-5040-03 | Jan 7, 2029 | |
Quezar 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation | DRP-4693-06 | Sep 6, 2028 | |
Quezar 50Losartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Guimhealth Pharmaceutical Distributor and DrugstoreImporter: Ambica International Corporation | DRP-6453-02 | Nov 27, 2030 | |
QxarLosartan Potassium | 50 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: Healthlink 211 Pharma, Inc. | DR-XY38659 | Oct 18, 2030 | |
RaptrasolLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15663-01 | Aug 16, 2029 | |
RaptrasolLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12412-05 | Jul 23, 2031 | |
RapzarLosartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-15663-03 | Aug 16, 2029 | |
RapzarLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | St. Raphael Archangel Pharmaceutical Product Distribution | DRP-12412-02 | Sep 22, 2031 | |
RegisartLosartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Regimed Pharmaceutical DistributorImporter: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-08 | May 26, 2028 | |
Regizar-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-15663-07 | Aug 16, 2029 | |
Regizar-50Losartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Regimed Pharmaceutical Distributor | DRP-12412-17 | Aug 3, 2031 | |
RetasarLosartan Potassium | 100 mg Film-Coated TabletAlu /Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Emil Pharmaceutical Industries Pvt. Ltd.India | Reta DrugImporter: Ambica International CorporationTrader: Chempro Pharma Pvt. Ltd. | DRP-10067-01 | May 26, 2028 | |
RetasarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | Reta DrugImporter: Aglobal Care, Inc. | DRP-8058-04 | Apr 29, 2031 | |
RetasarcLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Reta DrugImporter: Orange Biotec Inc. | DRP-15448-01 | Jul 10, 2029 | |
RetazarLosartan Potassium | 50 mg TabletAlu/PVC Blister Pack x 10’s (Box of 30’s; Box of 60's and Box of 100's) | RxVAT-exempt | Kopran LimitedIndia | Reta DrugImporter: Despina Pharma Inc. | DRP-13056-01 | Nov 23, 2027 | |
RetazartLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Reta DrugImporter: Medinova Pharmaceutical Inc. | DRP-8985-10 | Aug 18, 2031 | |
50 mg Film Coated TabletAlu/Red PVC Blister Pack x 10's (Box of 100's) | Rx | San Marino Laboratories CorporationPhilippines | — | DRP-12332 | Jul 20, 2027 | ||
Saphlor 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-14961 | Jan 20, 2032 | |
Saphlor 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Genom Biotech Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-14962 | Jan 20, 2032 | |
Saphlor-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences Inc. | DRP-10666 | Feb 2, 2031 | |
Saphlor-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Nelpa Lifesciences, Inc. | DRP-12531 | Sep 2, 2027 | |
Saphlor-50Losartan potassium | 50 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-10667 | Jan 30, 2030 | |
Saphlor-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Sai Parenterals Ltd.India | Nelpa Lifesciences, Inc. | DRP-12532 | Jan 23, 2031 | |
Saranto 50Losartan Potassium | 50mg Film-coated tabletAlu/ White Opaque PVC/PE/PVDC Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Aurobindo Pharma Limited (Unit III)India | AAA Pharma,Inc. | DR-XY41720 | Feb 22, 2028 | |
SartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 30’s | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | ECE Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-5040-01 | Jan 7, 2029 | |
Sartan 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | ECE Pharmaceuticals, Inc.Importer: Ambica International Corporation | DRP-4693-11 | Sep 6, 2028 | |
SartangoldLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's, and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories, Inc.Philippines | Brilliantmeed, Inc. | DRP-12412-18 | Aug 3, 2031 | |
Sartanova-100Losartan potassium | 100 mg Film-Coated TabletAlu/PVC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Ratnatris Pharmaceuticals Private LimitedIndia | GA2 Pharmaceutical Inc.Importer: Medinova Pharmaceutical Inc. | DRP-16506-01 | Apr 2, 2030 | |
Sartassium-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-4693-08 | Sep 6, 2028 | |
Sartassium-50Losartan potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mediwin PharmaceuticalsIndia | Ambitech Biopharmaceuticals Inc.Importer: Ambica International Corporation | DRP-6453-05 | Nov 27, 2030 | |
Sartollen 100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's, 60's, 90's and 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma Trading Inc.Importer: Nelpa Lifesciences, Inc. | DRP-12531-02 | Sep 2, 2027 | |
Sartollen 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Sapphire Lifesciences Pvt. Ltd.India | Ollen Pharma TradingImporter: Nelpa Lifesciences, Inc. | DRP-12532-02 | Sep 2, 2027 | |
SaztanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hiral Labs LimitedIndia | Medhart Pharma Inc.Importer: Aglobal Care, Inc. | DRP-8058-01 | Apr 29, 2031 | |
Shertan-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kain’s Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-13686-09 | Mar 28, 2028 | |
Shertan-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Kain's Trading Corp.Importer: Pharmakon Biotec Inc. | DRP-13687-13 | Mar 28, 2028 | |
Spartan 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | RL Pharma Enterprises Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-07 | Mar 28, 2028 | |
StarloLosartan Potassium | 100 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DRP-16773 | Dec 14, 2031 | |
StarloLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Saga LaboratoriesIndia | Hexagon Pharmaceuticals | DR-XY47605 | Dec 14, 2026 | |
StarloLosartan Potassium | 50 mg Film Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Saga Lifesciences LimitedIndia | Hexagon Pharmaceuticals | DRP-16771 | Dec 14, 2031 | |
StarloLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Saga LaboratoriesIndia | Hexagon Pharmaceuticals | DR-XY47606 | Dec 14, 2026 | |
SydentanLosartan Potassium | 100 mg Film-Coated TabletAlu/PVC White Opaque Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | Sydenham Pharmaceuticals, Inc. | DRP-1797 | Sep 29, 2029 | |
SydentanLosartan Potassium | 50 mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Sydenham Laboratories, Inc.Philippines | — | DR-XY36849 | Oct 21, 2029 | |
TanzaseLosartan Potassium | 50 mg TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 10's and 100's) | RxVAT-exempt | PharmEvo (Pvt.) Ltd.Pakistan | Accesspoint International Trading Inc. | DRP-5768 | Dec 4, 2028 | |
TechnozarLosartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-05 | Mar 8, 2028 | |
TechnozarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | One Technodrug Life Sciences Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-04 | Mar 28, 2028 | |
TenzorichLosartan Potassium | 50 mg Film-Coated TabletAlu / Alu Blister Pack x 10’s (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Medirich Pharma Distribution Corp.Importer: Pharmakon Biotec Inc. | DRP-13687-18 | Mar 28, 2028 | |
Torlos-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 50's and 100's) | RxVAT-exempt | TORRENT PHARMACEUTICALS LTD.India | TORRENT PHARMA PHILIPPINES, INC. | DRP-2845 | Jul 24, 2027 | |
UnbrandedLosartan Potassium | 100 mg TabletOpaque White PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Watsons Personal Care Stores (Philippines), Inc. | DRP-5096-01 | Dec 7, 2030 | |
UnbrandedLosartan Potassium | 100 mg TabletOpaque white PVC/Aluminum blister pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | Ritemed Phils., Inc. | DRP-5096-03 | Feb 12, 2032 | |
UnbrandedLosartan (as Potassium) | 100mg TabletAlu/Red PVC Blister pack x 10's (Box of 100's) | RxVAT-exempt | Drugmaker's Laboratories IncPhilippines | TGP Pharma Inc. | DRP-7208-01 | Oct 10, 2031 | |
UnbrandedLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Vamsler Phils. Incorporated | DR-XY45078 | Feb 17, 2031 | |
UnbrandedLosartan Potassium | 50 mg Film-Coated TabletAlu/Clear PVC Blister Pack x 10's Box of 100's; Alu/Clear PVC Blister Pack x 10's as Physician's Sample Box of 10's | RxVAT-exempt | Interphil Laboratories, Inc.Philippines | St. Joseph Drugstore | DRP-1456-05 | Mar 19, 2029 | |
UnbrandedLosartan (as Potassium) | 50 mg Film-Coated TabletAlu-Alu Blister Pack x 10's (Box of 30's) | RxVAT-exempt | XL Laboratories Pvt. Ltd.India | Ambicare Pharmaceuticals Inc.Importer: Ambica International Corporation | DRP-3183-06 | Jun 7, 2037 | |
UnbrandedLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s Box of 100's | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Diafarm Inc.Importer: Ambica International Corporation | DRP-5040-04 | Jan 7, 2029 | |
UnbrandedLosartan Potassium | 50 mg Film-Coated TabletOpaque white PVC/Aluminum Blister Pack x 10's (Box of 60's) | RxVAT-exempt | Pascual Laboratories, Inc.,Philippines | South Star Drug | DRP-5095-04 | Jan 23, 2032 | |
VALLOSARLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10’s (Box of 30’s and 100’s) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., LtdChina | SwissPharmatech Co.Importer: AMB HK Enterprises Inc. | DRP-8522-03 | Oct 25, 2029 | |
VamzarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Bulacan | Trader: Ultramed Pharma, Inc. | DR-XY45350 | Apr 29, 2031 | |
Vascure 50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Northmed Pharma and Medical Supplies DistributionImporter: Pharmakon Biotec Inc. | DRP-13687-17 | Mar 28, 2028 | |
VasotasLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | PSA Chemicals & Pharmaceuticals Pvt. Ltd.India | Suhitas Pharmaceuticals Inc.Importer: Orange Biotec Inc. | DRP-15448-05 | Jul 10, 2029 | |
VAZALIVELosartan Potassium | 50 mg Film Coated TabletAlu/Alu blister pack x 10’s (Box of 30's and 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Teramedix Pharma Trading Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-23 | Mar 28, 2028 | |
Vazortan 50Losartan Potassium | 50 mg Film-coated TabletAlu/Alu blister pack x 10's (Box of 100's) | RxVAT-exempt | Medley Pharmaceuticals LimitedIndia | Ambica International Corporation | DRP-10664 | Nov 3, 2031 | |
VenosartanLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10’s (Box of 30's and 100's) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | JMED PharmaImporter: Pharmakon Biotec, Inc. | DRP-13687-21 | Mar 28, 2028 | |
VivasartanLosartan Potassium | 100 mg Film-Coated TabletPVC/PVDC/Alu Blister Pack x 10's and 15's (Box of 30's) | RxVAT-exempt | Genveon Ilac Sanayi Ve Ticaret A.S.Turkey | Importer: Sandoz Philippines Corporation | DRP-2184 | Jul 7, 2029 | |
VivasartanLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's and 15's Box of 30's | RxVAT-exempt | Sandoz Grup Saglik Urunleri Ilaclari Sanayi Ve Tiracet A.S. (Gebze 2)Turkey | Importer: Sandoz Philippines Corporation | DRP-2183 | Jan 26, 2030 | |
VonsartanLosartan Potassium | 100 mg Film Coated TabletAlu/Red PVC Blister Pack x 10's and 20's (Box of 100's) | RxVAT-exempt | Vonwelt Inc.Philippines | — | DRP-13513 | Feb 16, 2027 | |
VonsartanLosartan Potassium | 100 mg Film-Coated TabeltAlu/Red PVC Blister Pack x 10's and 20's (Box of 100's) | RxVAT-exempt | Vonwelt Inc.Philippines | — | DR-XY44163 | Feb 16, 2027 | |
WelsartanLosartan Potassium | 50 mg Film-Coated TabletAlu/PVC/PVDC Blister Pack x 10's (Box of 30's and 100's) | RxVAT-exempt | Hebei Tiancheng Pharmaceutical Co., Ltd.China | Pharmacare Products CorporationImporter: AMB HK Enterprises Inc. | DRP-8522-07 | Oct 25, 2029 | |
WesartanLosartan Potassium | 50 mg TabletAlu-White Opaque PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | LifeSquare Laboratories, Inc.Philippines | Westpoint Pharma Inc. | DRP-4706-03 | Sep 22, 2031 | |
WilopresLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Willore Pharma Corporation | DRP-1667-01 | Aug 11, 2030 | |
WilopresLosartan Potassium | 50 mg Film Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Trader: Willore Pharma Corporation | DR-XY37022 | Nov 26, 2029 | |
YsartanLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 30's, 50's and 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Botika ni-Julia | DRP-12412-11 | Jul 31, 2031 | |
ZaranLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Gold Life Distribution Phils., Inc. | DR-XY37916 | May 11, 2030 | |
ZarnatLosartan Potassium | 100 mg Film-Coated TabletAlu/PV Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY33208 | Apr 16, 2031 | |
ZarnatLosartan Potassium | 50 mg Film-Coated TabletBlister Pack x 20's (Box of 100's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | Trader: Corbridge Group Phils., Inc. | DR-XY33519 | Jun 22, 2027 | |
ZarphilLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Phil Asia Pharma Inc.Importer: Ambica International Corporation | DRP-2591 | Jul 31, 2028 | |
ZarposeLosartan Potassium | 500 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Charmmed IncorporatedImporter: Ambica International Corporation | DRP-2591-01 | Apr 26, 2028 | |
Zartan-SLosartan Potassium | 100 mg Film-Coated TabletAlu/White PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Sigma Medical Solution Trading Co., Inc. | DRP-1667-06 | Aug 11, 2030 | |
Zartan-SLosartan Potassium | 50 mg Film-Coated TabletWhite PVDC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Hizon Laboratories, Inc.Philippines | Sigma Medical Solution Trading Co., Inc. | DRP-128-08 | Oct 10, 2030 | |
ZartapelLosartan Potassium | 50 mg Film-Coated TabletAlu-Opaque White PVC Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Azarias Pharmaceutical Laboratories Inc.Philippines | Errapel Pharmed Corp. | DRP-12412-09 | Aug 6, 2031 | |
ZebesarLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister pack x 10's (Box of 100's) | RxVAT-exempt | Zim Laboratories LimitedIndia | Zebe TradingImporter: Medinova Pharmaceutical Inc. | DRP-8985-11 | Aug 17, 2031 | |
Zelosart-100Losartan Potassium | 100 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-13686-07 | Mar 28, 2028 | |
Zelosart-50Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100’s) | RxVAT-exempt | Magbro Healthcare Pvt. Ltd.India | Zeldix Pharma Inc.Importer: Pharmakon Biotec Inc. | DRP-13687-08 | Mar 28, 2028 | |
ZilzartLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Synmedic LaboratoriesIndia | Quad-Gen PharmaceuticalsImporter: Ambica International Corporation | DRP-2591-06 | Apr 26, 2028 | |
Zilzart-SLosartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Stallion Laboratories Pvt. Ltd.India | Pharmasilv TradingImporter: Ambica International Corporation | DRP-5458-02 | Aug 18, 2029 | |
Zyltan 50Losartan Potassium | 50mg Film-Coated TabletAlu/White Opaque PVC Blister Pack x 10's Box of 100's | RxVAT-exempt | Troikaa Pharmaceuticals Ltd.India | Troikaa Pharmaceuticals Philippines, Inc. | DR-XY41018 | Jul 9, 2027 | |
(no brand name)Losartan Potassium | 100 mg Film-Coated TabletAlu/White PVC-PVDC Blister x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-11967 | May 25, 2027 | |
(no brand name)Losartan Potassium | 100 mg Film-Coated TabletAlu/PVC/PVDC Blister x 10's (Box of 30's) | RxVAT-exempt | United International Pharma Co. Ltd.Vietnam | Ritemed Phils., Inc. | DRP-12006 | May 27, 2027 | |
(no brand name)Losartan potassium | 50 mg Film-Coated TabletAlu/White PVC-PVDC Blister x 10's (Box of 30's) | RxVAT-exempt | Lloyd Laboratories, Inc.Philippines | — | DRP-11968 | May 25, 2027 | |
(no brand name)Losartan Potassium | 50 mg Film-Coated TabletAlu/Alu Blister Pack x 10's (Box of 30's & 100's) | RxVAT-exempt | Unique Pharmaceutical Laboratories (A Division of J.B. Chemicals & Pharmaceuticals Limited)India | Ambica International Corporation | DRP-12460 | Aug 12, 2027 | |
(no brand name)Losartan potassium | 50 mg Film-coated TabletBlister Pack x 10's (Box of 100's) | RxVAT-exempt | Plethico Pharmaceuticals Ltd.India | Medethix, Inc.Importer: I.E. Medica, Inc.Trader: Wiscon Pharmaceuticals Pvt. Ltd. | DRP-996-04 | Nov 12, 2027 | |
(no brand name)Losartan Potassium | 50 mg TabletAlu/Alu Blister Pack x 10's (Box of 100's) | RxVAT-exempt | Mankind Pharma Limited (Unit II)India | I.E. Medica Inc. | DRP-11012 | Jan 3, 2027 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
United States (label)
Dosage forms and strengths (US label) US FDA label
3 DOSAGE FORMS AND STRENGTHS COZAAR, 25 mg, are white, oval, film-coated tablets with code 951 on one side. COZAAR, 50 mg, are white, oval, film-coated tablets with code 952 on one side and scored on the other. COZAAR, 100 mg, are white, teardrop-shaped, film-coated tablets with code 960 on one side. Tablets: 25 mg; 50 mg; and 100 mg. (3)
Warnings/Precautions
The boxed warning is shown at the top of this page.
- Hypotension: Correct volume or salt depletion prior to administration of COZAAR. (5.2)
- Monitor renal function and potassium in susceptible patients. (5.3, 5.4)
5.1 Fetal Toxicity
5.1 Fetal Toxicity COZAAR can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.
Potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death. When pregnancy is detected, discontinue COZAAR as soon as possible [see Use in Specific Populations (8.1)].
5.2 Hypotension in Volume- or Salt-Depleted Patients
5.2 Hypotension in Volume- or Salt-Depleted Patients In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients (e.g., those being treated with high doses of diuretics), symptomatic hypotension may occur after initiation of treatment with COZAAR. Correct volume or salt depletion prior to administration of COZAAR [see Dosage and Administration (2.1)].
5.3 Renal Function Deterioration
5.3 Renal Function Deterioration Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on COZAAR.
Monitor renal function periodically in these patients. Consider withholding or discontinuing therapy in patients who develop a clinically significant decrease in renal function on COZAAR [see Drug Interactions (7.3) and Use in Specific Populations (8.7)].
5.4 Hyperkalemia
5.4 Hyperkalemia Monitor serum potassium periodically and treat appropriately. Dosage reduction or discontinuation of COZAAR may be required [see Adverse Reactions (6.1)]. Concomitant use of other drugs that may increase serum potassium may lead to hyperkalemia [see Drug Interactions (7.1)].
Drug interactions
| Drug or class | Severity | Effect | What to do |
|---|---|---|---|
| Potassium-raising drugs (potassium supplements, potassium-sparing diuretics, salt substitutes) | Adjust or monitor | Hyperkalemia. | Monitor serum potassium. |
| Lithium | Adjust or monitor | Higher lithium levels and toxicity. | Monitor lithium levels. |
| NSAIDs, including COX-2 inhibitors | Adjust or monitor | Worse kidney function, possible acute renal failure (older, volume-depleted or CKD patients); weaker antihypertensive effect. | Monitor kidney function periodically. |
| Aliskiren (in diabetes) | Avoid | Dual RAS blockade: hypotension, hyperkalemia, kidney function changes. | Contraindicated in patients with diabetes. |
| ACE inhibitors, other ARBs, aliskiren (dual RAS blockade) | Avoid | More hypotension, syncope, hyperkalemia and acute renal failure; no added benefit in VA NEPHRON-D. | Avoid routine combination; monitor blood pressure, kidney function and electrolytes if used. |
Severity scale (renalcarematters.com): Avoid: do not combine; Adjust or monitor: change the dose or monitor closely; Minor: usually no action.
renalcarematters.com, reviewed- Agents Increasing Serum Potassium: Risk of hyperkalemia. (7.1)
- Lithium: Risk of lithium toxicity. (7.2)
- NSAIDs: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects. (7.3)
- Dual Inhibition of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. (7.4)
7.1 Agents Increasing Serum Potassium
7.1 Agents Increasing Serum Potassium Coadministration of losartan with other drugs that raise serum potassium levels may result in hyperkalemia. Monitor serum potassium in such patients.
7.2 Lithium
7.2 Lithium Increases in serum lithium concentrations and lithium toxicity have been reported during concomitant administration of lithium with angiotensin II receptor antagonists. Monitor serum lithium levels during concomitant use.
7.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2…
7.3 Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) Including Selective Cyclooxygenase-2 Inhibitors (COX-2 Inhibitors) In patients who are elderly, volume-depleted (including those on diuretic therapy), or with compromised renal function, coadministration of NSAIDs, including selective COX-2 inhibitors, with angiotensin II receptor antagonists (including losartan) may result in deterioration of renal function, including possible acute renal failure. These effects are usually reversible.
Monitor renal function periodically in patients receiving losartan and NSAID therapy. The antihypertensive effect of angiotensin II receptor antagonists, including losartan, may be attenuated by NSAIDs, including selective COX-2 inhibitors.
7.4 Dual Blockade of the Renin-Angiotensin System (RAS)
7.4 Dual Blockade of the Renin-Angiotensin System (RAS) Dual blockade of the RAS with angiotensin receptor blockers, ACE inhibitors, or aliskiren is associated with increased risks of hypotension, syncope, hyperkalemia, and changes in renal function (including acute renal failure) compared to monotherapy. The Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) trial enrolled 1448 patients with type 2 diabetes, elevated urinary-albumin-to-creatinine ratio, and decreased estimated glomerular filtration rate (GFR 30 to 89.9 mL/min), randomized them to lisinopril or placebo on a background of losartan therapy and followed them for a median of 2.2 years.
Patients receiving the combination of losartan and lisinopril did not obtain any additional benefit compared to monotherapy for the combined endpoint of decline in GFR, end stage renal disease, or death, but experienced an increased incidence of hyperkalemia and acute kidney injury compared with the monotherapy group. In most patients no benefit has been associated with using two RAS inhibitors concomitantly.
In general, avoid combined use of RAS inhibitors. Closely monitor blood pressure, renal function, and electrolytes in patients on COZAAR and other agents that affect the RAS. Do not coadminister aliskiren with COZAAR in patients with diabetes. Avoid use of aliskiren with COZAAR in patients with renal impairment (GFR <60 mL/min).
Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. However, rifampin has been shown to decrease the AUC of losartan and its active metabolite by 30% and 40%, respectively. Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses.
Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. The AUC of active metabolite following oral losartan was not affected by erythromycin, an inhibitor of P450 3A4, but the AUC of losartan was increased by 30%. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.
Adverse reactions
Common
- Upper respiratory infection (8% vs 7% placebo)
- Dizziness (3% vs 2%)
- Nasal congestion (2% vs 1%)
- Back pain (2% vs 1%)
Serious
- Fetal toxicity (boxed warning)
- Hypotension in volume- or salt-depleted patients
- Kidney function deterioration, including acute renal failure
- Hyperkalemia
- Most common adverse reactions (incidence ≥2% and greater than placebo) are: dizziness, upper respiratory infection, nasal congestion, and back pain. (6.1)
- To report SUSPECTED ADVERSE REACTIONS, contact Organon LLC, a subsidiary of Organon & Co., at 1-844-674-3200 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
6.1 Clinical Trials Experience
6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Hypertension COZAAR has been evaluated for safety in more than 3300 adult patients treated for essential hypertension and 4058 patients/subjects overall.
Over 1200 patients were treated for over 6 months and more than 800 for over one year. Treatment with COZAAR was well-tolerated with an overall incidence of adverse events similar to that of placebo. In controlled clinical trials, discontinuation of therapy for adverse events occurred in 2.3% of patients treated with COZAAR and 3.7% of patients given placebo.
In 4 clinical trials involving over 1000 patients on various doses (10-150 mg) of losartan potassium and over 300 patients given placebo, the adverse events that occurred in ≥2% of patients treated with COZAAR and more commonly than placebo were: dizziness (3% vs. 2%), upper respiratory infection (8% vs. 7%), nasal congestion (2% vs. 1%), and back pain (2% vs. 1%). The following less common adverse reactions have been reported: Blood and lymphatic system disorders: Anemia.
Psychiatric disorders: Depression. Nervous system disorders: Somnolence, headache, sleep disorders, paresthesia, migraine. Ear and labyrinth disorders: Vertigo, tinnitus. Cardiac disorders: Palpitations, syncope, atrial fibrillation, CVA. Respiratory, thoracic and mediastinal disorders: Dyspnea. Gastrointestinal disorders: Abdominal pain, constipation, nausea, vomiting.
Skin and subcutaneous tissue disorders: Urticaria, pruritus, rash, photosensitivity. Musculoskeletal and connective tissue disorders: Myalgia, arthralgia. Reproductive system and breast disorders: Impotence. General disorders and administration site conditions: Edema. Cough Persistent dry cough (with an incidence of a few percent) has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy.
Two prospective, parallel-group, double-blind, randomized, controlled trials were conducted to assess the effects of losartan on the incidence of cough in hypertensive patients who had experienced cough while receiving ACE-inhibitor therapy. Patients who had typical ACE-inhibitor cough when challenged with lisinopril, whose cough disappeared on placebo, were randomized to losartan 50 mg, lisinopril 20 mg, or either placebo (one study, n=97) or 25 mg hydrochlorothiazide (n=135).
The double-blind treatment period lasted up to 8 weeks. The incidence of cough is shown in Table 1 below. Table 1 Study 1 Demographics = (89% Caucasian, 64% female) HCTZ Losartan Lisinopril Cough 25% 17% 69% Study 2 Demographics = (90% Caucasian, 51% female) Placebo Losartan Lisinopril Cough 35% 29% 62% These studies demonstrate that the incidence of cough associated with losartan therapy, in a population that all had cough associated with ACE-inhibitor therapy, is similar to that associated with hydrochlorothiazide or placebo therapy.
Cases of cough, including positive re-challenges, have been reported with the use of losartan in postmarketing experience. Hypertensive Patients with Left Ventricular Hypertrophy In the Losartan Intervention for Endpoint (LIFE) study, adverse reactions with COZAAR were similar to those reported previously for patients with hypertension.
Nephropathy in Type 2 Diabetic Patients In the Reduction of Endpoints in NIDDM with the Angiotensin II Receptor Antagonist Losartan (RENAAL) study involving 1513 patients treated with COZAAR or placebo, the overall incidences of reported adverse events were similar for the two groups. Discontinuations of COZAAR because of side effects were similar to placebo (19% for COZAAR, 24% for placebo).
The adverse events, regardless of drug relationship, reported with an incidence of ≥4% of patients treated with COZAAR and occurring with ≥2% difference in the losartan group vs. placebo on a background of conventional antihypertensive therapy, were asthenia/fatigue, chest pain, hypotension, orthostatic hypotension, diarrhea, anemia, hyperkalemia, hypoglycemia, back pain, muscular weakness, and urinary tract infection.
6.2 Postmarketing Experience
6.2 Postmarketing Experience The following additional adverse reactions have been reported in postmarketing experience with COZAAR. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably or to establish a causal relationship to drug exposure: Digestive: Hepatitis.
General Disorders and Administration Site Conditions: Malaise. Hematologic: Thrombocytopenia. Hypersensitivity: Angioedema, including swelling of the larynx and glottis, causing airway obstruction and/or swelling of the face, lips, pharynx, tongue, and/or swelling of the intestine has been reported; some of these patients previously experienced angioedema with other drugs including ACE inhibitors.
Vasculitis, including Henoch-Schönlein purpura, has been reported. Anaphylactic reactions have been reported. Metabolic and Nutrition: Hyponatremia. Musculoskeletal: Rhabdomyolysis. Nervous System Disorders: Dysgeusia. Skin: Erythroderma.
Adverse reaction frequency tables (US label) US FDA label
| Study 1Demographics = (89% Caucasian, 64% female) | HCTZ | Losartan | Lisinopril |
| Cough | 25% | 17% | 69% |
| Study 2Demographics = (90% Caucasian, 51% female) | Placebo | Losartan | Lisinopril |
| Cough | 35% | 29% | 62% |
Monitoring parameters
- Serum creatinine and potassium 2 to 4 weeks after starting or changing the dose; a creatinine rise up to 30% is expected and is not a reason to stop. Correct volume depletion before starting (label). KDIGO 2024 supports continuing the ARB when eGFR falls below 30. Kidney
- Serum potassium periodically
- Kidney function periodically, especially with renal artery stenosis, CKD, severe heart failure or volume depletion
- Blood pressure
- Stop at once if pregnancy is detected
Pregnancy considerations
Pregnancy (US label) US FDA label
8.1 Pregnancy Risk Summary COZAAR can cause fetal harm when administered to a pregnant woman. Use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. Most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system from other antihypertensive agents.
When pregnancy is detected, discontinue COZAAR as soon as possible (see Clinical Considerations). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.
Clinical Considerations Disease-associated Maternal and/or Embryo/Fetal Risk Hypertension in pregnancy increases the maternal risk for pre-eclampsia, gestational diabetes, premature delivery, and delivery complications (e.g., need for cesarean section, post-partum hemorrhage). Hypertension increases the fetal risk for intrauterine growth restriction and intrauterine death.
Pregnant women with hypertension should be carefully monitored and managed accordingly. Fetal/Neonatal Adverse Reactions Oligohydramnios in pregnant women who use drugs affecting the renin-angiotensin system in the second and third trimesters of pregnancy can result in the following: reduced fetal renal function leading to anuria and renal failure, fetal lung hypoplasia, skeletal deformations, including skull hypoplasia, hypotension, and death.
In the unusual case that there is no appropriate alternative to therapy with drugs affecting the renin-angiotensin system for a particular patient, apprise the mother of the potential risk to the fetus. In patients taking COZAAR during pregnancy, perform serial ultrasound examinations to assess the intra-amniotic environment.
Fetal testing may be appropriate, based on the week of gestation. If oligohydramnios is observed, discontinue COZAAR, unless it is considered lifesaving for the mother. Patients and physicians should be aware, however, that oligohydramnios may not appear until after the fetus has sustained irreversible injury. Closely observe neonates with histories of in utero exposure to COZAAR for hypotension, oliguria, and hyperkalemia.
In neonates with a history of in utero exposure to COZAAR, if oliguria or hypotension occurs, support blood pressure and renal perfusion. Exchange transfusions or dialysis may be required as a means of reversing hypotension and replacing renal function. Data Animal Data Losartan potassium was administered orally to rats during the period of late gestation through lactation (Gestation Day 15 through Lactation Day 20) at doses of 10, 25, and 100 mg/kg/day.
Losartan potassium has been shown to produce adverse effects in rat fetuses and neonates, including decreased body weight, delayed physical and behavioral development, mortality and renal toxicity. With the exception of neonatal weight gain (which was affected at doses as low as 10 mg/kg/day), doses associated with these effects exceeded 25 mg/kg/day (approximately three times the maximum recommended human dose of 100 mg on a mg/m 2 basis).
These findings are attributed to drug exposure in late gestation and during lactation. Significant levels of losartan and its active metabolite were shown to be present in rat fetal plasma during late gestation and in rat milk.
Mechanism of action
12.1 Mechanism of Action Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex.
Losartan and its principal active metabolite block the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT 1 receptor found in many tissues, (e.g., vascular smooth muscle, adrenal gland). There is also an AT 2 receptor found in many tissues but it is not known to be associated with cardiovascular homeostasis.
Neither losartan nor its principal active metabolite exhibits any partial agonist activity at the AT 1 receptor, and both have much greater affinity (about 1000-fold) for the AT 1 receptor than for the AT 2 receptor. In vitro binding studies indicate that losartan is a reversible, competitive inhibitor of the AT 1 receptor.
The active metabolite is 10 to 40 times more potent by weight than losartan and appears to be a reversible, non-competitive inhibitor of the AT 1 receptor. Neither losartan nor its active metabolite inhibits ACE (kininase II, the enzyme that converts angiotensin I to angiotensin II and degrades bradykinin), nor do they bind to or block other hormone receptors or ion channels known to be important in cardiovascular regulation.
US FDA labelPharmacodynamics
Pharmacodynamics (US label) US FDA label
12.2 Pharmacodynamics Losartan inhibits the pressor effect of angiotensin II (as well as angiotensin I) infusions. A dose of 100 mg inhibits the pressor effect by about 85% at peak with 25-40% inhibition persisting for 24 hours. Removal of the negative feedback of angiotensin II causes a doubling to tripling in plasma renin activity and consequent rise in angiotensin II plasma concentration in hypertensive patients.
Losartan does not affect the response to bradykinin, whereas ACE inhibitors increase the response to bradykinin. Aldosterone plasma concentrations fall following losartan administration. In spite of the effect of losartan on aldosterone secretion, very little effect on serum potassium was observed. The effect of losartan is substantially present within one week but in some studies the maximal effect occurred in 3-6 weeks.
In long-term follow-up studies (without placebo control) the effect of losartan appeared to be maintained for up to a year. There is no apparent rebound effect after abrupt withdrawal of losartan. There was essentially no change in average heart rate in losartan-treated patients in controlled trials.
Pharmacokinetics
Key PK parameters
| Bioavailability | About 33% (first-pass) |
|---|---|
| Time to peak | Losartan 1 hour; active metabolite 3 to 4 hours |
| Half-life | Losartan about 2 hours; active metabolite 6 to 9 hours |
| Half-life in kidney failure (ESKD) kidney | Not reported; AUC 50% to 90% higher at CrCl 30 to 74 mL/min (label) |
| Volume of distribution | Losartan about 34 L; metabolite about 12 L |
| Protein binding | Highly bound (free fraction 1.3% losartan, 0.2% metabolite) |
| Metabolism (CYP, transporters) | CYP2C9 and CYP3A4; about 14% converted to the active carboxylic acid metabolite |
| Active metabolites | Carboxylic acid metabolite (E-3174) |
| Renal excretion kidney | About 4% unchanged and 6% as active metabolite in urine (oral); about 35% of radiolabel in urine, 60% in feces |
| Dialyzability kidney | No: neither losartan nor its active metabolite is removed by hemodialysis (label). |
Elimination: Total plasma clearance of losartan and the active metabolite is about 600 mL/min and 50 mL/min, respectively, with renal clearance of about 75 mL/min and 25 mL/min, respectively.
The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours.
After single doses of losartan administered orally, about 4% of the dose is excreted unchanged in the urine and about 6% is excreted in urine as active metabolite.
Biliary excretion contributes to the elimination of losartan and its metabolites.
In this study, renal clearance was reduced by 55-85% for both losartan and its active metabolite in patients with mild or moderate renal insufficiency.
Pharmacokinetics (US label) US FDA label
12.3 Pharmacokinetics Absorption: Following oral administration, losartan is well absorbed and undergoes substantial first-pass metabolism. The systemic bioavailability of losartan is approximately 33%. Mean peak concentrations of losartan and its active metabolite are reached in 1 hour and in 3-4 hours, respectively. While maximum plasma concentrations of losartan and its active metabolite are approximately equal, the AUC (area under the curve) of the metabolite is about 4 times as great as that of losartan.
A meal slows absorption of losartan and decreases its C max but has only minor effects on losartan AUC or on the AUC of the metabolite (~10% decrease). The pharmacokinetics of losartan and its active metabolite are linear with oral losartan doses up to 200 mg and do not change over time. Distribution: The volume of distribution of losartan and the active metabolite is about 34 liters and 12 liters, respectively.
Both losartan and its active metabolite are highly bound to plasma proteins, primarily albumin, with plasma free fractions of 1.3% and 0.2%, respectively. Plasma protein binding is constant over the concentration range achieved with recommended doses. Studies in rats indicate that losartan crosses the blood-brain barrier poorly, if at all.
Metabolism: Losartan is an orally active agent that undergoes substantial first-pass metabolism by cytochrome P450 enzymes. It is converted, in part, to an active carboxylic acid metabolite that is responsible for most of the angiotensin II receptor antagonism that follows losartan treatment. About 14% of an orally-administered dose of losartan is converted to the active metabolite.
In addition to the active carboxylic acid metabolite, several inactive metabolites are formed. In vitro studies indicate that cytochrome P450 2C9 and 3A4 are involved in the biotransformation of losartan to its metabolites. Elimination: Total plasma clearance of losartan and the active metabolite is about 600 mL/min and 50 mL/min, respectively, with renal clearance of about 75 mL/min and 25 mL/min, respectively.
The terminal half-life of losartan is about 2 hours and of the metabolite is about 6-9 hours. After single doses of losartan administered orally, about 4% of the dose is excreted unchanged in the urine and about 6% is excreted in urine as active metabolite. Biliary excretion contributes to the elimination of losartan and its metabolites.
Following oral 14 C-labeled losartan, about 35% of radioactivity is recovered in the urine and about 60% in the feces. Following an intravenous dose of 14 C-labeled losartan, about 45% of radioactivity is recovered in the urine and 50% in the feces. Neither losartan nor its metabolite accumulates in plasma upon repeated once-daily dosing.
Specific Populations Pediatric: Pharmacokinetic parameters after multiple doses of losartan (average dose 0.7 mg/kg, range 0.36 to 0.97 mg/kg) as a tablet to 25 hypertensive patients aged 6 to 16 years are shown in Table 4 below. Pharmacokinetics of losartan and its active metabolite were generally similar across the studied age groups and similar to historical pharmacokinetic data in adults.
The principal pharmacokinetic parameters in adults and children are shown in the table below. Table 2: Pharmacokinetic Parameters in Hypertensive Adults and Children Age 6-16 Following Multiple Dosing Adults given 50 mg once daily for 7 days N=12 Age 6-16 given 0.7 mg/kg once daily for 7 days N=25 Parent Active Metabolite Parent Active Metabolite AUC 0-24 (ng∙hr/mL) Mean ± standard deviation 442 ± 173 1685 ± 452 368 ± 169 1866 ± 1076 C MAX (ng/mL) 224 ± 82 212 ± 73 141 ± 88 222 ± 127 T 1/2 (h) Harmonic mean and standard deviation 2.1 ± 0.70 7.4 ± 2.4 2.3 ± 0.8 5.6 ± 1.2 T PEAK (h) Median 0.9 3.5 2.0 4.1 CL REN (mL/min) 56 ± 23 20 ± 3 53 ± 33 17 ± 8 The bioavailability of the suspension formulation was compared with losartan tablets in healthy adults.
The suspension and tablet are similar in their bioavailability with respect to both losartan and the active metabolite [see Dosage and Administration (2.5)]. Geriatric and Gender: Losartan pharmacokinetics have been investigated in the elderly (65-75 years) and in both genders. Plasma concentrations of losartan and its active metabolite are similar in elderly and young hypertensives.
Plasma concentrations of losartan were about twice as high in female hypertensives as male hypertensives, but concentrations of the active metabolite were similar in males and females. No dosage adjustment is necessary [see Dosage and Administration (2.1)]. Race: Pharmacokinetic differences due to race have not been studied [see Use in Specific Populations (8.6)].
Renal Insufficiency: Following oral administration, plasma concentrations and AUCs of losartan and its active metabolite are increased by 50-90% in patients with mild (creatinine clearance of 50 to 74 mL/min) or moderate (creatinine clearance 30 to 49 mL/min) renal insufficiency. In this study, renal clearance was reduced by 55-85% for both losartan and its active metabolite in patients with mild or moderate renal insufficiency.
Neither losartan nor its active metabolite can be removed by hemodialysis [see Warnings and Precautions (5.3) and Use in Specific Populations (8.7)]. Hepatic Insufficiency: Following oral administration in patients with mild to moderate alcoholic cirrhosis of the liver, plasma concentrations of losartan and its active metabolite were, respectively, 5-times and about 1.7-times those in young male volunteers.
Compared to normal subjects the total plasma clearance of losartan in patients with hepatic insufficiency was about 50% lower and the oral bioavailability was about doubled. Use a starting dose of 25 mg for patients with mild to moderate hepatic impairment. COZAAR has not been studied in patients with severe hepatic impairment [see Dosage and Administration (2.4) and Use in Specific Populations (8.8)].
Drug Interactions No clinically significant drug interactions have been found in studies of losartan potassium with hydrochlorothiazide, digoxin, warfarin, cimetidine and phenobarbital. However, rifampin has been shown to decrease the AUC of losartan and its active metabolite by 30% and 40%, respectively. Fluconazole, an inhibitor of cytochrome P450 2C9, decreased the AUC of the active metabolite by approximately 40%, but increased the AUC of losartan by approximately 70% following multiple doses.
Conversion of losartan to its active metabolite after intravenous administration is not affected by ketoconazole, an inhibitor of P450 3A4. The AUC of active metabolite following oral losartan was not affected by erythromycin, an inhibitor of P450 3A4, but the AUC of losartan was increased by 30%. The pharmacodynamic consequences of concomitant use of losartan and inhibitors of P450 2C9 have not been examined.
Subjects who do not metabolize losartan to active metabolite have been shown to have a specific, rare defect in cytochrome P450 2C9. These data suggest that the conversion of losartan to its active metabolite is mediated primarily by P450 2C9 and not P450 3A4.
Formulary and pricing (Philippines)
Government price references
| Preparation | Price (PHP) | Unit | Type |
|---|---|---|---|
| Losartan 50 mg Tablet | ₱0.70–₱7.00Reference ₱0.80 | per tablet | DPRI procurement range |
| Losartan 100 mg Tablet | ₱1.70–₱8.00Reference ₱2.50 | per tablet | DPRI procurement range |
| 50 mg (as potassium) tablet | ₱9.00 | per tablet | PhilHealth GAMOT fixed fee |
| 100 mg (as potassium) tablet | ₱12.00 | per tablet | PhilHealth GAMOT fixed fee |
PhilHealth GAMOT fixed fee paid to the accredited GAMOT pharmacy per unit dispensed Range = lowest-highest procurement price (highest usable only in GIDA areas); reference_price = 2021 DPRI ceiling (median)
These are government procurement and reimbursement references, not retail prices. Sources:
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf, as of September 17, 2021
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf, as of October 13, 2026
Formulary and coverage
| Philippine National Formulary | Listed as Losartan (as potassium salt) |
| PNF listing | Oral: 50 mg and 100 mg tablet |
| PhilHealth GAMOT | Yes (listed since July 28, 2025) |
| PhilHealth YAKAP (formerly Konsulta) | Yes |
Sources:
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf, as of November 2, 2022
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- U.S. Food and Drug Administration. COZAAR · Organon LLC [US FDA-approved label, version 9, January 20, 2026]. Via DailyMed/openFDA. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PNF Essential Medicines List, 8th ed. (as of November 2, 2022), DOH; https://www.philhealth.gov.ph/partners/providers/pdf/PNF-EML_11022022.pdf
- PhilHealth Circular No. 2026-0018, Expanding Access to Outpatient First-line Anti-TB Drugs through PhilHealth GAMOT, Annex A.i GAMOT List (81 molecules); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- PhilHealth Circular No. 2026-0018, Annex A.2 GAMOT Fixed Fee Schedule (249 preparations; fees otherwise unchanged from PC2025-0013); https://www.philhealth.gov.ph/circulars/2026/PC-2026-0018.pdf
- DOH Drug Price Reference Index (DPRI) 2021, 9th edition (as of September 17, 2021); https://caro.doh.gov.ph/wp-content/uploads/2021/09/2021DPRI-as-of-9-17-2021.pdf
- Organon LLC. (2026). COZAAR (losartan potassium) [Prescribing information; US FDA-approved label, NDA020386, set ID 9949448f-c3b9-44ee-94ed-c1aca8c90f39, version effective January 20, 2026]. DailyMed, U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9949448f-c3b9-44ee-94ed-c1aca8c90f39
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. (2024). KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney International, 105(4S), S117–S314. https://doi.org/10.1016/j.kint.2023.10.018
- Schwartz, G. J., Muñoz, A., Schneider, M. F., Mak, R. H., Kaskel, F., Warady, B. A., & Furth, S. L. (2009). New equations to estimate GFR in children with CKD. Journal of the American Society of Nephrology, 20(3), 629–637. https://doi.org/10.1681/ASN.2008030287
renalcarematters.com content: Kidney and pediatric dosing: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026. Dosing, interaction, adverse-effect and monitoring summary: reviewed by William Gregory M. Rivero, MD, FPCP, DPSN on November 16, 2026.
Last updated: .



